Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Is Dual Lipid-Lowering Therapy Better?

Atherosclerosis; 2018 Feb; Gragnano, et al

Dual-lipid-lowering therapy (DULT) is more effective than statin monotherapy in high-risk patients with coronary artery disease (CAD), according to a recent review. The review determined that in recent trials, combination strategies involving a statin and non-statin agent have been shown to promote coronary atherosclerosis regression and improve cardiovascular (CV) outcomes in patients with moderate-to-high CV risk. The authors concluded:

  • DULT should be implemented in patients above the recommended low-density lipoprotein cholesterol (LDL-C) target on a high-intensity statin and might be proposed as a first-line strategy in certain patients regardless of their LDL-C levels.
  • Preference for 1 of the 2 strategies (NPC1L1 blockade or PCSK9 inhibition) should be evaluated case by case, according to the patient’s characteristics, LDL-C levels, risk profile, and national regulatory agency indications.

Citation:

Gragnano F, Calabró P. Role of dual lipid-lowering therapy in coronary atherosclerosis regression: Evidence from recent studies. Atherosclerosis. 2018;269:219-228. doi:10.1016/j.atherosclerosis.2018.01.012.

This Week's Must Reads

Improving CV Health in Women Through Provider Collaboration, Circulation; ePub 2018 May 10; Brown, et al

Burden of AF With Risk of Stroke in Paroxysmal AF, JAMA Cardiol; ePub 2018 May 16; Go, et al

OSA & Risk of Hospitalization in Patients with HFpEF, Am J Cardiol; ePub 2018 May 11; Abdullah, et al

Air Pollution Exposure in Pregnancy & Risk of High BP, Hypertension; ePub 2018 May 14; Zhang, et al

Total & CV Mortality After LDL-C Lowering, JAMA; 2018 Apr 17; Navarese, et al

Must Reads in Hypercholesterolemia

Total & CV Mortality After LDL-C Lowering, JAMA; 2018 Apr 17; Navarese, et al

PCSK9 Inhibitors for Tx of Hypercholesterolemia, Ann Pharmacother; ePub 2018 Apr 1; Patel, et al

High-Intensity Statin Use and LDL-C Control, J Clin Lipidol; ePub 2018 Apr 26; Lamprecht Jr, et al

Improving Adherence with ASCVD Interventions, Clin Cardiol; ePub 2018 Apr 17; Fentanes, et al

Lipid Screening in Children with NAFLD, J Pediatr; ePub 2018 Apr 13; Harlow, et al